This trial will test whether the drug DZP can help improve the symptoms of people with moderate to severe disease activity, when used alongside SOC medication.
1 Primary · 16 Secondary · Reporting Duration: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
450 Total Participants · 2 Treatment Groups
Primary Treatment: DZP · Has Placebo Group · Phase 3
Age Any Age · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Did not meet criteria||100.0%|